FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With RET Gene Mutations or Fusions by Kim, Janice, Bradford, Diana, Larkins, Erin, Pai-Scherf, Lee H, Chatterjee, Somak, Mishra-Kalyani, Pallavi S, Wearne, Emily, Helms, Whitney S, Ayyoub, Amal, Bi, Youwei, Sun, Jielin, Charlab, Rosane, Liu, Jiang, Zhao, Hong, Liang, Dun, Ghosh, Soma, Philip, Reena, Pazdur, Richard, Theoret, Marc R, Beaver, Julia A, Singh, Harpreet

Get full text

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC by Akinboro, Oladimeji, Larkins, Erin, Pai-Scherf, Lee H, Mathieu, Luckson N, Ren, Yi, Cheng, Joyce, Fiero, Mallorie H, Fu, Wentao, Bi, Youwei, Kalavar, Shyam, Jafri, Samina, Mishra-Kalyani, Pallavi S, Fourie Zirkelbach, Jeanne, Li, Hongshan, Zhao, Hong, He, Kun, Helms, Whitney S, Chuk, Meredith K, Wang, Min, Bulatao, Ilynn, Herz, Jonathan, Osborn, Blaire L, Xu, Yuan, Liu, Jiang, Gong, Yutao, Sickafuse, Sharon, Cohen, Rebecca, Donoghue, Martha, Pazdur, Richard, Beaver, Julia A, Singh, Harpreet

Get full text

Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials by Theoret, Marc R, Pai-Scherf, Lee H, Chuk, Meredith K, Prowell, Tatiana M, Balasubramaniam, Sanjeeve, Kim, Tamy, Kim, Geoffrey, Kluetz, Paul G, Keegan, Patricia, Pazdur, Richard

Get full text

Hepatotoxicity in Cancer Patients Receiving erb-38, a Recombinant Immunotoxin That Targets the erbB2 Receptor by Pai-Scherf, L H, Villa, J, Pearson, D, Watson, T, Liu, E, Willingham, M C, Pastan, I

Get full text

Imaging and Phase I Study of 111In- and 90Y-labeled Anti-LewisY Monoclonal Antibody B3 by Pai-Scherf, L H, Carrasquillo, J A, Paik, C, Gansow, O, Whatley, M, Pearson, D, Webber, K, Hamilton, M, Allegra, C, Brechbiel, M, Willingham, M C, Pastan, I

Get full text